Loading page
Loading page
Loading substance route
Heavy doses carry elevated risk of psychotic symptoms, mania, and delirium.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
3-MeO-PCE is considered highly addictive with a high potential for adverse side effects. It has been reported to be more habit-forming than other dissociatives such as ketamine, MXE, diphenidine, and ephenidine. Compulsive redosing is commonly reported, particularly when smoked or vaporized due to the abrupt onset and offset via this route. Multiple reports describe users becoming seriously addicted daily users.
Cravings and withdrawal effects may occur upon sudden cessation after addiction has developed, though the specific nature and severity of withdrawal symptoms are not well documented.
The exact toxic dosage is unknown. The toxicity of recreational 3-MeO-PCE use has not been studied in any scientific context due to its very brief history of human usage.
Chronic heavy use may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence; however, these effects appear less severe than with ketamine due to the higher potency of 3-MeO-PCE requiring significantly smaller quantities to achieve effects.
3-MeO-PCE has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, MXE, or diphenidine. Heavy doses and repeated use substantially increase this risk. These effects typically occur during the offset of the experience but can also manifest during onset or come up. Numerous experience reports describe states of psychotic delirium, amnesia, mania, and other serious consequences following abuse of this substance.
Seizures have been reported as a potential effect, though frequency, severity, and precipitating conditions are not well documented.
3-MeO-PCE emerged on the online research chemical market around 2010, where it was marketed as a grey-area legal alternative to controlled dissociatives such as PCP and ketamine. The compound represents part of the broader wave of designer arylcyclohexylamines that became available through online…
Controlled under Ley de drogas (Ley 20000). As an ether of PCE, 3-MeO-PCE falls under the law's prohibition of all esters and ethers of PCE.
Classified as a controlled substance. Possession, production, and distribution are prohibited under national drug legislation.
Classified as an illegal drug under national legislation. Possession, production, supply, and import are prohibited offenses.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import for market distribution, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalty.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause added via S.I. 2013/239, effective February 26, 2013. This clause encompasses N-alkyl derivatives of 1-phenylcyclohexylamine with alkoxy substitution in the phenyl ring. Possession, production, supply, and import are illegal.
13 sources cited
